By Kim Han-joo
SEOUL, Nov. 7 (Yonhap) -- South Korean pharmaceutical firm Samsung Bioepis Co. said Thursday it has entered into a new commercialization agreement worth US$370 million with U.S. partner Biogen.
Under the partnership, Biogen will be responsible of marketing and sales of Samsung Bioepis' two biosimilars -- SB11 and SB15 -- and two other ophthalmology biosimilars that are currently in development.
The agreement also gives Biogen the option to extend its existing 10-year commercialization agreement for three anti-TNF biosimilars in Europe by five years.
"By building on this collaboration, we are excited to potentially expand the opportunity for patients living with ophthalmological conditions, who do not have access to life-changing medicines," Samsung Bioepis CEO Christopher Hansung Ko said in a press release.
Samsung Bioepis, established in 2012, currently has biosimilars approved and marketed across Europe and the U.S. -- Benepali, Imraldi, Ontruzant and Flixabi.
S. Korea's space program opens new chapter with rocket engine launch, satellites
Samsung aims to overcome biz hurdles through 180 tln won investment
Naver's relinquishing of news editing first step to addressing opinion rigging concerns
(News Focus) All eyes on Samsung's stock split, impact on share value
Samsung's stock split move to make it possible for ordinary investors to buy-sell shares